UniQure announced that the U.S. FDA agreed that mid-stage study data could support an accelerated approval filing for its Huntington's disease gene therapy. On June 18, the FDA officially opened a pathway for the accelerated approval filing of the treatment. This development marks a significant regulatory milestone in potentially bringing the therapy to market sooner.
